FDA Approves Admelog (insulin lispro) Short-Acting "Follow-On" Insulin Product to Treat Diabetes

Article Link: FDA Approves Admelog (insulin lispro) Short-Acting “Follow-On” Insulin Product to Treat Diabetes

December 11, 2017 — The U.S. Food and Drug Administration today approved Admelog (insulin lispro injection), a short-acting insulin indicated to improve control in blood sugar levels in adults and pediatric patients aged 3 years and older with type…

Source: FDA New Drug Approvals